1st Annual Acute Lymphoblastic Leukemia Fellows Scholar Program
The 1st Annual Acute Lymphoblastic Leukemia Fellows Scholar Program (ALLFSP) is an intensive, multi-day immersion program focused on all clinical aspects of ALL. Targeting hematology/oncology fellows of training programs across the US, the Acute Lymphoblastic Leukemia Fellows Scholar Program offers fellows the opportunity to interact with nationally recognized ALL experts in both didactic and small group learning opportunities.
All registrants are required to present an ALL/LBL clinical case during their assigned case study breakout session. All case study presentations must be submitted in advance in PowerPoint format and include all pertinent diagnostic imaging, disease characteristics, and lab findings. The resident’s presentation should total no more than 6-8 slides; the attendees will have approximately 10 minutes for presentation and discussion. Case study submission requirements will be emailed to residents following registration.
Please send your nominated Fellow the PDF letter attached to your email in order to complete registration. It contains the registration website and the password.
Supported by an independent educational grant from Jazz Pharmaceuticals
Hematology/oncology fellows in training programs across the US
1. Examine the rationale for using asparaginase in treatment of acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) and explore the different asparaginase containing ALL/LBL treatment regimens.
2. Evaluate key clinical trial data of the different asparaginase containing regimens and apply that knowledge to selecting optimal asparaginase-containing treatments based on patient-specific factors as well as the latest data.
3. Identify and distinguish between the different asparaginase products available, including their dose, route, formulation, and PK profiles and use in pediatric, young adult and adult populations.
4. Recognize asparaginase related toxicities that lead to poorer patient prognosis and identify the difference between asparaginase infusion reaction, clinical and subclinical hypersensitivity, and silent inactivation.
5. Develop monitoring and interpretation strategies for serum asparaginase levels to optimize treatment.
6. Using a case-based approach, formulate clinical strategies for patients undergoing treatment with asparaginase-containing regimens, focusing on efficacy and safety of different formulations, and approaches to monitor asparaginase levels while also preventing and mitigating asparaginase-related toxicities.
|ALLFSP Resources.pdf||158.75 KB|
|2-Sided ASNase Assay Algorithm.pdf||256.21 KB|
|ASCO Fertility preservation guidelines 2018.pdf||562.28 KB|
|Bibliography--ALLFSP 2023.pdf||290.89 KB|
|Handout--ASNase Products and Considerations.pdf||1.34 MB|
|Handout--Toxicities Part 1.pdf||1.1 MB|
|Handout--Toxicities Part 2.pdf||1.05 MB|
|Handout--Transplantation in RR ALL.pdf||1.15 MB|
|Handout--Barriers and Future Directions.pdf||914.76 KB|
|Hanout--Clinical Biological Features of ALL.pdf||2.05 MB|
|Handout--Overview of ASNase Containing Regimens.pdf||3.57 MB|
January 31, 2023
2:30-3:00 PM Snack Break and Check-in
3:00-3:15 PM Introductory Remarks
3:15-4:00 PM Clinical and Biologic Features of Acute Lymphoblastic Leukemia *
4:00-5:30 PM Diving into the Data: Overview of Asparaginase-containing Regimens in ALL/LBL and considerations for use in Pediatric, AYA, and Adult Patients*
5:30-6:15 PM Q&A Panel/Break
6:30-8:30 PM Welcome Dinner and Meet-the-Faculty
February 1, 2023
7:30-8:00 AM Buffet Breakfast
8:00-9:30 AM Asparaginase-containing Products: Review of Available Formulations and Implications in Practice*
9:30-9:45 AM Q&A Panel/Break
9:45-10:45 AM Asparaginase-related Toxicities Part 1*: Big Picture, Hepatotoxicity, and Pancreatitis
10:45-11:45 AM Asparaginase-related Toxicities Part 2*: Thrombosis, Hyperlipidemia, and Hyperglycemia
11:45 AM-12:00 PM Q&A Panel
12:00-1:00 PM Buffet Lunch
1-00-2:00 PM The Role of Transplantation in R/R ALL*/ Barriers in Clinical Practice and Future Directions*
2:00-2:30 PM Q&A Panel/Break
2:30-5:00 PM Case Study Workshops
5:30 PM-7:00 PM Cocktail Reception/Buffet Dinner
February 2, 2023
7:00 AM-8:00 AM Breakfast/Departures
*Sessions considered for Category 1 AMA PRA credit (ACCME).
Emily K. Curran, MD
Hematology & Oncology
University of Cincinnati College of Medicine
Ryan D. Cassaday, MD
Division of Hematology
University of Washington School of Medicine
Clinical Research Division
Fred Hutch Cancer Center
Adam Duvall, MD, MPH
Assistant Professor of Medicine
University of Chicago Medicine
Luke D. Maese, DO
Associate Professor (Clinical)
University of Utah
Salt Lake City, UT
Professor of Paediatrics
Department of Paediatrics and Adolescent Medicine,
The Juliane Marie Centre and the Institute for Clinical Medicine
University of Copenhagen
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 6.0 hours AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.